Learn from John Venditto, MD, in this complimentary, non-CME webinar, held Wednesday, December 2, from 7:00–8:30 pm CST. He will discuss the disease burden and pathophysiology for acute ischemic stroke (AIS); the risk of recurrent stroke/transient ischemic attack (TIA); and the patient care pathway.
- Understand the disease burden and pathophysiology for AIS, and appreciate the underlying alterations in platelet physiology and phenotype in the context of AIS or high-risk TIA.
- Learn about the use of BRILINTA in patients with AIS and high-risk TIA and the differentiation of P2Y12 inhibitor use in this patient population.
- Appreciate the evidence and indications for BRILINTA across the spectrum of atherosclerotic and atherothrombotic disease by understanding the BRILINTA Pivotal Trials and the recently published THALES Trial.
Limited space is available for the live session—secure your place by registering today!
John Venditto, MD
Senior Field Medical Director
US Medical Affairs – Cardiovascular
AstraZeneca Pharmaceuticals LP
This content was developed by AstraZeneca and is neither endorsed by the CNS nor does it represent the views of the CNS. Click here to visit their website and learn more.